# DNAtrix

Source: https://onco.cc/companies/dnatrix/  
OnCo record `dnatrix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DNAtrix developed viruses, based on a common cold virus, that are engineered to infect and kill cancer cells. Its main candidate, DNX-2401, was tested in brain tumours including glioblastoma and a childhood brainstem tumour. The company has announced nothing since 2021 and its website no longer works.

## Summary

DNAtrix described itself in 2021 as a privately held company developing virus-driven immunotherapies for cancer, based on an adenovirus engineered to infect and kill cancer cells selectively. DNX-2401 (formerly Delta-24-RGD-4C) was its lead candidate; the company then said it would enter a global pivotal phase 3 study in recurrent glioblastoma, and that it held FDA Fast Track and Rare Pediatric Disease designations for diffuse intrinsic pontine glioma, where it was being tested in a phase 1 study. DNX-2440 is an adenovirus expressing OX40 ligand, first dosed in March 2021 in people with resectable colorectal liver metastases. On ClinicalTrials.gov, DNAtrix-sponsored studies of DNX-2401 in recurrent malignant glioma, with pembrolizumab, and with interferon gamma are completed; its DNX-2440 liver metastasis study (NCT04714983) is suspended, with the reason given as "DNAtrix management decision not based on study design, safety, or site performance". An MD Anderson phase 1 trial of DNX-2401 delivered in mesenchymal stem cells for recurrent high-grade glioma (NCT03896568) is listed as recruiting.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: DNAtrix, Inc.
- HQ: Houston, TX
- Type: biotech

## Notes

- Whether DNAtrix still operates could not be confirmed. Its domain dnatrix.com was serving unrelated spam on 3 November 2026, so no website is recorded. No company announcement later than March 2021 was found, and the phase 3 glioblastoma study the company described then was not found as a DNAtrix-sponsored record on ClinicalTrials.gov. Stage is left blank for that reason. Founding year not verified. Headquarters is the Houston dateline of the 2021 release. The 2021 release names Morningside Ventures and Mercury Fund as investors; neither has an investor record in OnCo. A Navarra phase 1 trial in newly diagnosed DIPG (NCT03178032) is completed. The trials have no trial records in OnCo, so they are linked below rather than in trials.

## Sources

- DNX-2440 first patient dosed, March 2021 (press release): https://www.biospace.com/dnatrix-announces-first-patient-dosed-in-clinical-study-of-dnx-2440-an-ox40-ligand-expressing-immunotherapy-in-colorectal-cancer-and-other-cancers-with-liver-metastasis
- ClinicalTrials.gov: NCT00805376, DNX-2401 in recurrent malignant gliomas: https://clinicaltrials.gov/study/NCT00805376
- ClinicalTrials.gov: NCT04714983, DNX-2440 in colorectal liver metastasis (suspended): https://clinicaltrials.gov/study/NCT04714983
- ClinicalTrials.gov: NCT03896568, MSC-DNX-2401 in recurrent high-grade glioma: https://clinicaltrials.gov/study/NCT03896568
- ClinicalTrials.gov: NCT03178032, DNX-2401 in DIPG: https://clinicaltrials.gov/study/NCT03178032

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)

---
JSON: https://onco.cc/api/v1/entities/dnatrix.json